Literature DB >> 216330

Some observations on the opiate peptides and schizophrenia.

S J Watson, H Akil, P A Berger, J D Barchas.   

Abstract

With the discovery of the opiate peptides, several major avenues of research became apparent. These peptides produced a great deal of focused attention on their anatomy, biochemistry, and physiology. In this article, we present an overview of some of the main research issues and recent findings in the field of opiate peptides. The possible relationship of the opiate peptide neuronal systems to schizophrenia is discussed in light of attempts to alter schizophrenic symptoms with opiate antagonists, beta-endorphin, and dialysis. It is hypothesized that if the opiate peptides are involved in schizophrenia, then their involvement with dopamine systems and/or with stress responses may be critical.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 216330     DOI: 10.1001/archpsyc.1979.01780010041004

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  7 in total

1.  Further speculations on possible dopamine-opioid link in autism.

Authors:  R Sandyk
Journal:  J Autism Dev Disord       Date:  1986-03

2.  Opioid peptides as neuroregulators: potential areas for the study of genetic-behavioral mechanisms.

Authors:  J D Barchas; S Sullivan
Journal:  Behav Genet       Date:  1982-02       Impact factor: 2.805

3.  Alterations in nociception and body temperature after intracisternal administration of neurotensin, beta-endorphin, other endogenous peptides, and morphine.

Authors:  C B Nemeroff; A J Osbahr; P J Manberg; G N Ervin; A J Prange
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

4.  Immunoreactive beta-endorphin and adrenocorticotropin in human cerebrospinal fluid.

Authors:  K Nakao; S Oki; I Tanaka; K Horii; Y Nakai; T Furui; M Fukushima; A Kuwayama; N Kageyama; H Imura
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

5.  Assessment of naltrexone in the treatment of schizophrenia.

Authors:  M J Gitlin; R H Gerner; M Rosenblatt
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

Review 6.  Peptide neuroregulators: the opioid system as a model.

Authors:  J D Barchas; C Evans; G R Elliott; P A Berger
Journal:  Yale J Biol Med       Date:  1985 Nov-Dec

7.  Opioid antagonists are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of controlled trials.

Authors:  Samuel D Clark; Jared X Van Snellenberg; Jacqueline M Lawson; Anissa Abi-Dargham
Journal:  Neuropsychopharmacology       Date:  2020-06-09       Impact factor: 7.853

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.